IBA Molecular North America, Inc. (IBA Molecular) announced the signing of a 3-year group purchasing agreement with Premier, Inc. (Premier), a leading health care improvement company, to offer PET radiopharmaceuticals, including 18F-Fluorodeoxyglucose (FDG), a diagnostic radiotracer used in oncology, neurology and cardiology, to Premier member imaging centers across the country.

Watch a fly-through of Glass Brain, a 3D imagining of the human brain by researchers at the University of California San Francisco. This video shows the 3D brain model made possible by electroencephalography data and white matter tract reconstruction from MRI diffusion tensor imaging. UCSF is using the technology to research possible treatments for neurodegenerative disease.

The human genome was first mapped just a little over a decade ago. Its 3 billion bits of DNA are the pages of the human instruction manual. Read this great review featuring Eric S. Lander from MIT, Harvard, and the Broad Institute in Cambridge to see how far we've come and what the future of genomics holds.

The shape of cancer genomics may be a new calling card for 3D oncologic imaging. Studying the formation of cancer cell genomes could potentially provide more information about a patient's cancer than just focusing on genetic expression. Scientists at McGill University in Montreal are finding that the form of a cancer cell genome can even tell them what subtype of cancer a patient has.

In an article published in the ICD10 monitor, Shannon DeConda, the founder and president of the National Alliance of Medical Auditing Specialists, compares the financial burdens brought on by EHR and ICD-10. In preparation for the ICD-10 implementation, hospital systems and larger health care facilities have large budgets planned for 2015, and many have already invested a significant outlay of money in education and training to meet the fall 2014 deadline. There also is the risk that unpracticed ICD-10 coding skills could diminish over the next 18 months. 

Biopharmaceutical giant Bristol-Myers Squibb now holds the power on a pipeline of neurodegenerative disease therapies after buying San Francisco-based iPierian for $175 million.

June 7-11, 2014St. Louis, MO 

Advanced gene sequencing has found a single genetic mutation essential for a brain disorder that has been plaguing Turkish families for centuries.